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Molecular Characterization  
of Growth Hormone-producing 
Tumors in the GC Rat Model  
of Acromegaly
Juan F. Martín-Rodríguez1,2, Jose L. Muñoz-Bravo1,2, Alejandro Ibañez-Costa3, 
Laura Fernandez-Maza4, Marcin Balcerzyk4, Rocío Leal-Campanario5, Raúl M. Luque3, 
Justo P. Castaño3, Eva Venegas-Moreno1,2, Alfonso Soto-Moreno1,2, Alfonso Leal-Cerro2,* & 
David A. Cano1,2,*
Acromegaly is a disorder resulting from excessive production of growth hormone (GH) and 
consequent increase of insulin-like growth factor 1 (IGF-I), most frequently caused by pituitary 
adenomas. Elevated GH and IGF-I levels results in wide range of somatic, cardiovascular, endocrine, 
metabolic, and gastrointestinal morbidities. Subcutaneous implantation of the GH-secreting GC cell 
line in rats leads to the formation of tumors. GC tumor-bearing rats develop characteristics that 
resemble human acromegaly including gigantism and visceromegaly. However, GC tumors remain 
poorly characterized at a molecular level. In the present work, we report a detailed histological 
and molecular characterization of GC tumors using immunohistochemistry, molecular biology and 
imaging techniques. GC tumors display histopathological and molecular features of human GH-
producing tumors, including hormone production, cell architecture, senescence activation and 
alterations in cell cycle gene expression. Furthermore, GC tumors cells displayed sensitivity to 
somatostatin analogues, drugs that are currently used in the treatment of human GH-producing 
adenomas, thus supporting the GC tumor model as a translational tool to evaluate therapeutic 
agents. The information obtained would help to maximize the usefulness of the GC rat model for 
research and preclinical studies in GH-secreting tumors.
Acromegaly is a disorder resulting from excessive production of growth hormone (GH) and conse-
quent increase of insulin-like growth factor 1 (IGF-I), most frequently caused by pituitary adenomas1. 
Elevated GH and IGF-I levels result in wide range of somatic, cardiovascular, endocrine, metabolic, and 
gastrointestinal morbidities1,2. If untreated, acromegaly leads to reduced life expectancy due primarily 
to cardiovascular disease3. Achieving biochemical control of the disease restores life expectancy to levels 
similar to that observed in the general population4. Therefore, the main goal of treatment for acromegaly 
is to normalize both GH and IGF-I levels5. Currently available treatment options for acromegaly include 
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surgery, radiotherapy and drug therapy. Three types of medications are available for the treatment of 
acromegaly: somatostatin analogs, dopamine agonists, and GH receptor antagonists2,6. However, the cur-
rently available therapies fail to control disease activity in a significant number of patients underscoring 
the need to develop novel therapeutic approaches7.
Animal models constitute critical tools for evaluating new therapeutic strategies before clinical testing. 
Several animal models have been developed to study the effects of chronic GH excess, including exoge-
nous administration of GH, transgenic GH overexpression, and implantation of GH-producing cells8–10. 
The subcutaneous implantation of GH-secreting GC cell line in Wistar Furth rats results in the forma-
tion of solid, functional tumors8. This acromegaly-like rat model has been successfully used to analyze 
the effects of chronic GH exposure on target tissues such as cardiac cells, nephrons11 and hypothalamic 
neurons12. However, GC tumors remain poorly characterized at a molecular level. In the present work, 
we report a detailed histological and molecular characterization of GC tumors using immunohistochem-
istry, molecular biology and imaging techniques that reveal that GC tumors exhibit histopathological 
and molecular features reminiscent of human GH-producing tumors. We also report proof-of-concept 
studies with somatostatin analogues that validate the GC tumor model as a translational tool to evaluate 
therapeutic agents. The information obtained would help to maximize the usefulness of the GC rat model 
for research and preclinical studies in GH-secreting tumors.
Results
Acromegaly features of GC rats are reversible upon surgical removal of tumors. Wistar Furth 
rats implanted with GC cells developed tumors in around 90% of animals injected. GC cells-grafted 
rats show a remarkable increase in body weight two weeks after cell implantation, as compared to vehi-
cle-treated rats (Fig. 1A,B). Body weight significantly decreased after tumor removal, reaching equivalent 
body weight to age-matched vehicle-treated rats. Naive tumor-bearing rats showed reduced life expectancy 
Figure 1. Phenotypic characterization of the acromegaly-like GC rat model. (A) Left panel. 
Representative picture of a rat (right) bearing a GC tumor (circled in red dashed lines) 8 weeks after 
subcutaneous injection of GC cells compared to a vehicle-treated rat (left). Right panel. (B) Increase in 
body weight after subcutaneous injection of GC cells compared to PBS-injected control rats. Removal of 
the tumor by surgery blocks the increase in body weight. P < 0.0001. Error bars missing in B is due to 
the small size of s.e.m. in those data points (C) Survival curve of GC tumor-bearing and control rats. GC 
tumor-bearing rats display increase mortality life expectancy as compared to both tumorectomized and 
vehicle-treated rats (logrank test’s P < 0.001) (D) Increased heart size in GC tumor-bearing rats (9 weeks 
after GC cells implantation) compared to compared to both tumorectomized (4 weeks after tumor resection) 
and vehicle-treated rats. Increased blood GH (E) and IGF-I levels (F) compared to both tumorectomized 
(4 weeks after tumor resection and vehicle-treated rats. n = 5 samples per group. Data are mean ± s.e.m. 
*P < 0.05.
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(median life expectancy = 9 weeks after GC cell implantation) as compared to both tumorectomized and 
vehicle-treated rats while survival curves of tumorectomized rats did not differ from vehicle-treated rats 
(Fig.  1C). As previously documented8,12, increased size was observed in a number of organs, namely 
spleen, and heart in GC tumor-bearing rats. After tumor resection, the size of these organs reverted to 
normal levels (Fig.  1D and Supplementary Table 1). Naive tumor-bearing rats showed elevated serum 
levels of GH and IGF-I, while normal levels of these hormones were found in both tumorectomized 
and vehicle-treated rats (Fig.  1E,F). Normal serum prolactin levels were found in tumor-bearing rats 
confirming that GC tumors produce exclusively GH (Supplementary Figure 1).
Tumor growth kinetics of GC tumors. Longitudinal noninvasive imaging allows monitoring of 
tumor growth providing a useful tool for evaluation of therapeutic agents. To visualize early tumor 
development and monitor tumor growth in GC rats, we used [18F]FDG-PET and [11C]Met-PET, com-
bined with computerized tomography. An increase in maximal and median standard uptake value (SUV 
med) at the site of the injection in GC rats compared to vehicle-treated rats was observed as early as 
7 days after cell implantation although this increase was not statistically significant (Fig. 2A,D,E). One 
week later, when tumors became palpable, FDG uptake at the site of the GC cell injection was signifi-
cantly increased (Fig. 2B,D,E). This increase in FDG uptake in GC rats persisted three weeks after the cell 
injection (Fig. 2C,D,E). At this time point, a significant increase in tumor volume was found (Fig. 2F). 
GC tumors continued to grow over several weeks and developed areas with low FDG uptake (Fig. 2G, 
bottom). To monitor metabolic activity in these large tumors, [11C]Met-PET, which provides more sen-
sitivity in pituitary adenomas that are characterized by elevated amino acid metabolism, was performed. 
Eight weeks after the injection, tumor metabolic activity was predominantly located at the periphery of 
the tumors (Fig.  2G top), in agreement with the central necrotic areas observed at gross examination 
(see below). Using a 1-compartment model to fit PET data, two different regions with distinctive [11C]
Met uptake were identified in the tumors. Areas with high metabolic activity were mainly localized at 
the periphery of the tumor while areas with reduced metabolic activity were found in the center of the 
tumor (Fig.  2G top, H). Thus, the pattern of high protein synthesis determined by [11C]Met-PET/CT 
(Fig. 2G top) is similar to the pattern of glucose metabolism determined by [18F]FDG-PET/CT (Fig. 2G 
bottom). The kinetic modeling of [11C]Met uptake using one tissue compartment model showed that 
the unidirectional transport of the tracer from blood compartment to the first tissue compartment K1 
(Fig. 2I) as well as total distribution volume Vt (Fig. 2J) was higher in active tumor tissue compared to 
necrotic tumor tissue or muscle control tissue. Thus, kinetic modeling of PET data in GC rats indicates 
that GC tumors develop large areas with low metabolic activity after several weeks of growth.
Histological characterization of GC tumors. Gross morphology analysis of GC tumors revealed 
well-defined, solid, encapsulated tumors (Supplementary Figure 2). No distant metastases were observed 
in GC tumor-bearing rats at any time point analyzed (out of more than 30 rats analyzed). Histological 
analysis of 3-week-old tumors revealed glandular regions composed of cells displaying typical endocrine 
cell morphology (small round cells with a big nucleus, highly acidophilic) (Fig. 3A) arranged in clusters 
around big blood vessels (Fig. 3A,B). Consistent with the relatively rapid growth observed with the imag-
ing data, GC tumor cells were highly proliferative (Ki-67 index: 31.7 ± 8.8) (Supplementary Figure  3). 
However, small areas of necrotic tissue were found adjacent to glandular tissue (Fig. 3A,B). Tumors at 
later stages display a marked increase in the size and number of necrotic areas (Supplementary Figure 4). 
This increased cell death observed in GC tumors did not appear to be due to massive cell apoptosis; only 
a few, scattered apoptotic cells were found in tumors sections (Fig. 3C). As expected, GC tumors were 
composed exclusively of GH-producing cells; no immunoreactivity for other pituitary hormones such 
as prolactin and ACTH was detected (Fig.  3D–I). To provide a further histological characterization of 
GC tumors, we analyzed the expression of cell adhesion proteins which have been associated with major 
features of pituitary adenomas such as size, proliferation and invasion13. The expression pattern of the 
cell adhesion molecules ß-catenin and N-cadherin in GC tumor cells were similar to that observed in 
normal rat pituitary (Fig. 3J,K,N,O). However, no expression of E-cadherin was observed in GC tumor 
cells (Fig.  3L,P). The sparsely granulated subtype of human GH-producing pituitary adenomas display 
decreased E-cadherin expression. Based on GH immunoreactivity, GC tumors seem to be more similar 
to the human densely granulated subtype of human GH-producing pituitary tumors. Densely exhibit 
strong, diffuse cytoplasmic accumulation of GH compared to the focal and weak GH immunoreactiv-
ity typical of sparsely granulated somatotroph adenomas14. Sparsely granulated somatotroph adenoma 
type can be unequivocally identified by the presence of fibrous bodies (also called globules) composed 
of keratins 8/1814. Immunohistochemistry for keratin 18 in GC tumors did not reveal the presence of 
fibrous bodies. keratin 18 exhibited perinuclear accumulation similar to that found in normal rat pitu-
itary (Fig. 3M,Q).
Senescence and cell cycle regulation analysis of GC tumors. Increased senescence has been 
hypothesized to explain the benign nature of human pituitary adenomas15,16. To determine whether 
cellular senescence was activated in GC tumors, we performed senescence-associated β -galactosidase 
(SA-β -Gal) staining on whole-mount as well as frozen sections of GC tumors. A prominent SA-β -Gal 
staining was observed in GC tumors (Fig. 4A,B). As expected, SA-β -Gal activity was observed only in 
www.nature.com/scientificreports/
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Figure 2. Molecular imaging with FDG- and Met-PET/CT. Representative [18F]FDG images (transverse, 
sagittal, lateral) of established GC tumors after 7 (A), 14 (B) and 21 (C) days after subcutaneous injection 
of the cells. A longitudinal CT section is also shown in right bottom panels. White arrowheads mark the 
localization of the tumor. [18F]FDG uptake expressed as maximum standard uptake value (SUV) (D) and 
mean value (E) of established GC tumors after 7, 14 and 21 days after subcutaneous injection of the cells. 
(F) Tumor volumes derived from SUV data in GC tumor. (G) Representative [11C]Met-PET (top) and [18F]
FDG -PET (bottom) images (transverse, sagittal, lateral) of GC tumors 54 days after subcutaneous injection of 
the cells. Asterisks mark areas with reduced metabolic activity. (H) Top graph- Time activity curves of [11C]
Met-PET/CT: red- necrotic zone of the tumor, blue-active area of the tumor, black—muscle in contralateral 
hind leg. Bottom graph. Time-activity curve of the active and necrotic zone of the tumor showing tracer 
accumulation over the first approximately 10 min, followed by a plateau phase (plateau value: 559.7 kBq/
cc; 95% confidence interval [479.4–640]). The data of the active area of the tumor fitted to a one phase 
association model (R2: 0.88; P < 0.05). (I) Kinetic analysis performed by fitting a standard 2-parameter, 
one-tissue compartment model to the dynamic PET data. k1 (transport from arterial plasma to tissue); k2 
(transport from tissue to arterial plasma). K1 values are higher in the active part of the tumor active part 
and the necrotic and between active part and the muscle. (J) Same data for Vt, total distribution volume. 
*P < 0.05.
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Figure 3. Histological characterization of GC tumors. (A) Hematoxylin/Eosin staining of 3-week-old GC 
tumor sections shows glandular regions composed of cells displaying typical endocrine cell morphology 
(inset) arranged in clusters. Areas of necrosis are observed (asterisks). (B) GC tumor cells arrange in clusters 
around blood vessels as shown by immunohistochemical staining for PECAM-1. Asterisks indicate areas 
of necrosis. (C) A few, scattered, apoptotic cells (arrowheads) are observed in GC tumors. GC tumors 
are composed exclusively of GH-producing cells (D). No prolactin (E) and ACTH (F) accumulation is 
observed in GC tumors. Robust expression of GH (G), prolactin (H) and ACTH (I) is found in normal rat 
pituitary. (J–O) Accumulation of cell adhesion proteins in GC tumors. Robust ß-catenin (J), N-cadherin 
(K) accumulation is observed in GC tumor cells. Almost no accumulation of E-Cadherin is observed in GC 
tumors cells (L). Robust accumulation of ß-catenin (M), N-cadherin (N) and E-cadherin (O) in normal rat 
pituitary. Perinuclear accumulation of keratin 18 in GC tumors (M) and normal rat pituitary (N).
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6SCIENtIFIC REPORTS | 5:16298 | DOI: 10.1038/srep16298
Figure 4. Senescence and cell cycle proteins in GC tumors. Robust Senescence-associated β -galactosidase 
(SA-β -Gal) accumulation was observed in GC tumors both in paraffin sections of whole mount SA-β -Gal-
stained tumors (A) and in cryogenic sections stained for SA-β -Gal (B). SA-β -Gal accumulation was 
observed only in non-proliferative GC tumor cells (C). The boxed areas are shown in higher magnification 
in C’ and C”. Increased, nuclear accumulation of the DNA damage response protein γ H2AX in GC 
tumors (D) compared to normal rat pituitary (E). Note that a few pituitary cells display cytoplasmic (likely 
unspecific) γ H2AX signal. Confocal microscope analysis showing GH/γ H2AX co-localization in GC tumor 
cells (F–H). (H) 3D reconstruction of the Z-stack for the pictures shown in (F,G). Increased accumulation 
of cyclin-dependent kinase inhibitor p21 in GC tumors (I) compared to normal rat pituitary (M). No 
expression of cyclin-dependent kinase inhibitor p27 is observed in GC tumors (K) but it is homogeneously 
expressed in normal rat pituitary (N). (L) Western blot analysis of p16 and p18 in 3 independent normal 
rat pituitary samples and 4 independent GC tumor samples. PTTG1 is overexpressed in GC tumors (O) 
compared to normal rat pituitary (P).
www.nature.com/scientificreports/
7SCIENtIFIC REPORTS | 5:16298 | DOI: 10.1038/srep16298
non-proliferative tumoral GC cells (Fig. 4C). Robust accumulation of another surrogate marker of senes-
cence, the DNA damage response protein γ H2AX, was found in GC tumors (Fig. 4D,E). Co-localization 
of γ H2AX and GH was determined by thorough confocal microscope analysis confirming that GC tumor 
cells display activation of senescence markers (Fig. 4F–H and Supplementary Figure 5). Cellular senes-
cence is associated with the activation of cell cycle inhibitors16. In agreement with this, we observed 
robust expression of the cyclin-dependent kinase inhibitor p21 in GC tumors whereas no expression 
was detected in normal rat pituitary (Fig.  4J,M). In contrast, the expression of the cyclin-dependent 
kinase inhibitor p27 was markedly reduced in GC tumors compared to normal pituitary (Fig.  4K,N). 
Germ-line mutations in Cdkn1b gene encoding the p27 protein predispose to pituitary adenoma for-
mation in both rats and humans17. Sequencing of the Cdkn1b gene in GC tumors, performed as pre-
viously described17, did not reveal any mutations. Two other cyclin-dependent kinase inhibitor, p16 
and p18, has also been reported downregulated on pituitary adenomas18. Western blot analysis also 
revealed a downregulation of p18 expression in GC tumors compared to normal rat pituitary (Fig.  4L 
and Supplementary Figure  6). p16 levels were similar between GC tumors and pituitary (Fig.  4L and 
Supplementary Figure 6). Overexpression of pituitary tumor-transforming gene 1 (PTTG1) is frequently 
observed in human GH-secreting tumors and it has been suggested to be related to induction of cellular 
senescence19. In concordance with these human studies, GC tumors exhibit increased PTTG1 expression 
compared to normal rat pituitary (Fig. 4O,P and Supplementary Figure 7).
Effect of somatostatin inhibitors on primary cell cultures from GC tumors. To evaluate the 
usefulness of GC tumors as a model for testing of therapeutic agents, we decided to determine whether 
GC tumor cells were sensitive to somatostatin analogues. Somatostatin analogues are the primary current 
medical treatment for GH-producing pituitary adenomas acting primarily as inhibitors of GH secre-
tion (although tumor growth might also be affected)6,7. As a first approach, we examined somatostatin 
receptor expression in GC tumors by quantitative real time PCR analysis. Sstr1 and Sstr2 were highly 
expressed followed by Sstr5 and Sstr3 (Fig. 5A). As a comparison, we measured somatostatin receptor 
expression in normal rat pituitary. Sstr5 and Sstr2 displayed the highest expression followed in normal 
rat pituitaries followed by Sstr1, and Sstr3. Sstr1 was the only Sstr subtype that displayed a statistically 
significant difference in gene expression between GC tumors and normal rat pituitary (Fig.  5A). We 
also measured the expression of the receptor for the Growth hormone-releasing hormone (GHRH), 
another hormone-regulatory pathway suggested to be implicated in GH-secreting adenoma formation20. 
Although we detected expression of GHRH receptor in normal pituitary, almost no expression could be 
observed in GC tumors (Supplementary Figure 8). We next determined the in vitro response of GC tumor 
cells to somatostatin analogues. To this end, primary cell cultures were obtained from 3-week-old GC 
tumors and the effect of the somatostatin analogues SOM-230 (multireceptor ligand), octreotide (higher 
affinity to Sstr2) and BIM-23120 (Sstr2 specific) on GH secretion and cell proliferation was measured. 
The three somatostatin analogues significantly inhibited GH release in GC tumor cultures (Fig. 5B), with 
BIM-23120 showing the highest inhibitory effect (34.3%) followed by octreotide (28.3%) and SOM-230 
(19%). A statistically significant decrease in cell proliferation was observed in GC tumor cultures treated 
with octreotide and BIM-23120, but not with SOM-230 (Fig. 5C). Altogether these results indicate that 
GC tumors are sensitive to somatostatin analogues.
Discussion
Preclinical animal models play a central role in understanding the biology and pathophysiology of tumor 
formation as well as in the testing of therapies. There is a paucity of animal models that faithfully reca-
pitulate GH-secreting tumors21. The GC acromegaly-like rat model remains largely under-recognized 
in the field of pituitary tumor research. We have revisited the GC rat model to perform an extensive 
histopathological and molecular characterization of the GC tumors that should further facilitate the use 
of this model by the pituitary research community.
The phenotypic data of the GC rats reported here are in agreement with previous findings8,12 and fur-
ther clarify the phenotype of this acromegaly animal model. GC cells-grafted rats display a rapid increase 
in body length and weight, as early as two weeks after cell implantation. This increase in body weight is 
concomitant with a marked elevation in serum levels of GH and IGF-I. In addition to increased body 
weight, GC cells-grafted rats display other classical human acromegaly traits such as splenomegaly and 
enlargement of the heart. Increased mortality was observed in GC tumor-bearing rats. Autopsy analysis 
could not conclusively demonstrate the underlying cause of this increased mortality but cardiovascular 
and respiratory disease might be associated8, as it has been previously shown in human acromegaly and 
transgenic mouse models of acromegaly3,10,22. Nevertheless, the increased mortality of GC rats seems to 
be directly due to the presence of the tumor since tumorectomized rats do not display reduced survival. 
The resection of the tumor causes a relatively drop of body weight in GC rats, reaching levels similar to 
those observed in control rats within a few weeks. This decrease in body weight was concomitant with 
a marked reduction of serum GH and IGF-I levels. These results are in agreement with studies showing 
that the body weight of patients with GH-producing adenomas rapidly decrease after successful surgical 
treatment23. Tumor resection also causes normalization in the weight of organs of GC tumor-bearing 
rats including the spleen and heart. No analysis of cardiac function in GC rats was performed in our 
study but it is tempting to speculate this normalization in the weight of the heart might be associated 
www.nature.com/scientificreports/
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with improvement in cardiac function as it has been shown in human patients after successful biochem-
ical control of acromegaly24. Nevertheless, this phenotypic analysis illustrate how the GC rat model, in 
contrast to other animal models of GH excess such as GH-overexpressing transgenic mice, offers the 
advantage of allowing to study the sequelae caused by excess of GH/IGF-I levels even after normalization 
of the circulating GH/IGF-I levels by surgical removal of the tumor.
In our hands, Wistar Furth rats implanted with GC cells developed palpable tumors between 2–3 
weeks after cell implantation. In agreement with this, significant increases in [18F]FDG consumption 
in GC tumors were observed starting from the second week after cell implantation. There was a trend 
towards increased [18F]FDG signal as early as 7 days after cell implantation but it was not statistically 
significant, probably due to the relatively small number of rats analyzed. [18F]FDG-PET imaging also 
allowed us to non-invasively measure the volume of the GC tumors finding a marked increase in tumor 
volume between 2 and 3 weeks after cell implantation. GC tumors continued to grow over several weeks. 
In these large tumor xenografts, regions of higher and lower [18F]FDG consumption were observed. 
Kinetic modeling of [11C]Met uptake confirmed the formation of areas with low metabolic activity on 
6–8 week-old GC tumors. This decrease in metabolic activity is likely due to the formation of internal 
tumor necrosis within these relatively large xenografts. Thus, based on our micro PET-CT results, three 
stages of tumor progression in the GC rat model could be broadly defined. During the first two weeks 
after GC cell implantation increased metabolic activity is observed in tumoral tissue. A marked increased 
Figure 5. Expression profile and effect of somatostatin analogues on GH secretion and cell proliferation 
in cultures from GC tumors. (A) Expression profile of somatostatin receptor (Sstr) subtypes in GC 
tumors (n = 5). mRNA copy number was adjusted by expression of a control gene (beta-actin) (B) Effect 
of 4 h treatment with somatostatin analogues (SOM-230, Octreotide and BIM-23120) at 100 nM on GH 
secretion in cultures from GC tumors. Values are expressed as percent of fetal bovine serum (FBS)-treated 
control cells (set at 100%; n = 3; 3–5 wells/treatment). (C) Cell viability in culture of GC tumors treated 
with somatostatin analogues (SOM-230, Octreotide and BIM-23120) at 100 nM for 24, 48 and 72 hours as 
compared with FBS-treated control cells. Values are expressed as percent of FBS-treated controls (set at 
100%; n = 3; 3–5 wells/treatment). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.
www.nature.com/scientificreports/
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in tumor volume occur after three weeks of growth. At later stages (6–7 weeks after cell implantation), 
internal areas with decreased metabolic activity (likely necrotic areas as evidenced by histological obser-
vations) are developed in the tumors. Thus, this pattern of the progression of GC tumor growth should 
be taken into account when evaluating therapeutic agents in this rat model of acromegaly. PET scans 
have shown to be a valuable technique for the diagnosis and management of pituitary adenomas25,26. Our 
PET results obtained in GC tumors are consistent with studies performed in human subjects that demon-
strate that GH-secreting adenomas display high metabolic activity assessed by both [18F]FDG-PET and 
[11C]Met-PET imaging25–28.
Histological examination demonstrated that subcutaneously grown GC tumors recapitulate the 
morphology of human pituitary adenomas. Typically, GC tumor cells were relatively small with a high 
nuclear/cytoplasmic ratio. Based on GH immunoreactivity and keratin 18 accumulation, GC tumors 
are reminiscent of the human densely granulated subtype of human GH-producing pituitary tumors. 
In humans, pituitary adenomas that produce both GH and prolactin, and (more rarely) both GH and 
ACTH, are found20,29. GC tumors were composed exclusively of GH-producing cells with no evidence 
of activation of expression of prolactin or ACTH at any of the stages analyzed, consistent with what has 
been previously reported for GC cells grown under standard cell culture conditions30. Thus, the GC rat 
model represents a homogeneous in vivo model of GH-producing adenomas. GC tumor cells appear 
to arrange in clusters around blood vessels. Regions of the tumors distant from blood vessels contain 
necrotic areas. These necrotic areas are particularly prominent in advanced stages when the size of the 
tumors is markedly increased consistent with the micro PET-CT findings showing areas with lower 
metabolic activity. These results suggest that lack of blood flow may inhibit GC tumor growth and lead 
to necrosis, likely due to hypoxia and/or lack of nutrients.
Altered expression of cell adhesion proteins such as N-cadherin, E-cadherin and ß-catenin has been 
associated with the formation of pituitary adenomas13. Our immunohistochemical analysis of these pro-
teins in GC tumor cells revealed strong, membranous expression of N-cadherin and ß-catenin, similar to 
that observed in normal rat pituitary gland (our data and31). However, expression of E-cadherin appears 
greatly reduced in GC tumors. Interestingly, decreased E-cadherin expression has been reported in differ-
ent types of human pituitary adenomas, including GH-producing adenomas32,33. This low expression of 
E-cadherin appears to be linked to increased invasiveness in human somatotroph pituitary adenomas32. 
Despite the low expression of E-cadherin displayed by GC tumors, no signs of malignant transformation 
or local invasiveness are observed in GC cells-grafted rats. Thus, GC tumors display a benign behavior 
similarly to what it is commonly observed in human somatotroph pituitary adenomas (or other types 
of pituitary adenomas, for that matter)34. It has been suggested that activation of cellular senescence 
might underlie the generally benign nature of pituitary adenomas compared to other types of cancer15,16. 
Thus, senescence markers such as cyclin-dependent kinase inhibitor p21 and senescence-associated 
β -galactosidase are induced in most of human GH-secreting adenomas, but not in aggressive pitui-
tary carcinomas35,36. In agreement with this notion, GC tumors display induction of p21 expression 
and senescence-associated ß-galactosidase activity. In the majority of human GH-producing pituitary 
adenomas, p21-dependent senescence is associated with Pttg-1 overexpression36. In agreement with this 
human data, GC tumors display robust PTTG-1 expression. In contrast to the robust expression of the 
cyclin-dependent kinase inhibitor p21, a dramatic reduction in the expression of the cyclin-dependent 
kinase inhibitor p27 is observed in GC tumors. Although p27 expression is down regulated in pituitary 
adenomas37,38 it should be noted that the majority of GH-secreting adenomas display p27 accumulation. 
Downregulation of two other cyclin-dependent kinase inhibitor, p16 and p18, has also been reported on 
pituitary adenomas18. Western blot analysis revealed a downregulation of p18 expression in GC tumors 
compared to normal rat pituitary. p16 levels were similar between GC tumors and pituitary but we 
should note the p16 levels were very low in both cases and thus, we have might not been able to detect 
subtle differences. Thus, our data indicate that GC tumors display alterations in the expression of several 
cell cycle related genes. Some of these cell cycle proteins display a pattern reminiscent of that observed 
in human GH-secreting adenomas while others not. Altogether, our results are consistent with the strong 
body of evidence that indicates that cell cycle deregulation is significantly involved in pituitary tumori-
genesis (for reviews, see18).
Inhibition of somatostatin receptor (SSTR) activity by somatostatin analogues is the main medical 
treatment for GH-producing pituitary adenomas2,6,7. The expression pattern of SSTR subtypes appears to 
correlate with the response to treatment with somatostatin analogues39–41. Indeed, quantification of SSTR 
subtype expression is currently being explored as a potential prognostic marker in human GH-secreting 
adenomas42. In GH-secreting adenomas, SSTR2 and SSTR5 are predominantly expressed followed by 
SSTR3 and SSTR1, while SSTR4 is virtually undetectable40,43,44. Rat GC tumors display a somewhat sim-
ilar expression pattern of Sstr subtypes, but Sstr1 expression in GC tumors was higher compared to what 
it has been observed in human GH-secreting adenomas. The elevated Sstr1 expression in GC tumors 
does not seem to be due to species differences since the Sstr expression pattern in normal pituitary is 
similar to that described in normal human pituitary45. Indeed, Sstr1 was the only Sstr subtype that dis-
played a statistically significant difference in expression between GC tumors and normal rat pituitary. 
The relevance of this high Sstr1 expression in GC cells on GH secretion is unclear since conflicting results 
have been reported. A previous study performed in GC cells in culture reported that inhibition of Sstr1 
efficiently blocked GH release46 but no Sstr1 binding was detected in radioligand binding experiments47. 
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It is interesting to note that despite the general low SSTR1 expression levels observed in GH-secreting 
adenomas, SSTR1 selective agonists have been shown to inhibit GH release from human GH-secreting 
adenomas in vitro48,49. Thus, these functional studies suggest that SSTR1 may also play a role in the reg-
ulation of GH secretion in human GH-secreting adenomas. Nevertheless, our Sstr expression results in 
GC tumors obtained by quantitative RT-PCR are in agreement with the Sstr expression pattern observed 
in GC cells grown under standard culture conditions by other techniques such as fluorescent immunola-
belling assays50. Increased expression of the GHRH receptor, (another hormone-regulatory pathway that 
might be involved in GH-secreting adenoma formation20 has been reported in agressive somatotroph 
adenomas51. We could not detect Ghrh expression in GC tumors indicating that this pathway does not 
play a significant role in GC tumor growth. To this regard, it is important to mention that a truncated 
form of the GHRH with defective function have been identified in GH-producing pituitary adenomas52, 
thus raising questions about the relevance of this pathway in pituitary adenomas.
To further validate the GC model as a translational tool to evaluate therapeutic agents, we established 
primary cell cultures from GC rat tumors and tested the effect of three different somatostatin analogues 
in GH secretion and cell proliferation. The somatostatin analogues chosen display slightly different affin-
ity patterns to somatostatin receptor subtypes. Octreotide is a clinically used somatostatin analogue that 
binds primarily to SSTR2 and to a lesser extent to SSTR5, BIM-23120 exhibits a very specific affin-
ity to SSTR2, whereas SOM-230 is a multi-somatostatin receptor ligand with high affinity for SSTR1, 
SSTR2, SSTR3 and SSTR542,53,54. These somatostatin analogues have been previously shown to inhibit GH 
secretion in primary cultures of human GH-secreting adenomas (for reviews, see55,56). In keeping with 
these observations, all somatostatin analogues cause a marked decrease in GH secretion in GC tumor 
cells. BIM-23120 and octreotide exhibit the highest inhibitory effect on GH secretion in GC tumors 
cells, likely due to the elevated expression of Sstr2 observed in GC tumors. Besides the inhibitor effects 
on GH secretion, somatostatin analogues display an antiproliferative effect in primary cultures from 
human GH-producing pituitary adenomas (for reviews, see57). In GC primary tumor cultures we observe 
that octreotide and BIM-23120, but not SOM-230, cause a decrease in cell proliferation. Interestingly, 
although SOM-230 exhibits an inhibitory effect on GH secretion, yet it does not affect cell proliferation 
in GC primary cultures. To this regard, it has been previously shown that the inhibition of cell prolifer-
ation by somatostatin analogues might occur independently of the effects on GH secretion in dispersed 
human GH-secreting pituitary adenoma cells in vitro. This dissociation of effects on GH secretion and 
cell proliferation by somatostatin analogues might be due to differences in receptor concentration and the 
SSTR subtypes expressed58. Although in vivo studies with somatostatin analogues such as BIM-23120 or 
SOM-230 are needed to fully validate the GC rat model for pharmacological studies, our in vitro exper-
iments constitute simple proof-of-concept studies that support the use of the GC bearing-tumor rats for 
the testing of therapeutic agents.
In summary, despite the obvious experimental differences between human GH-secreting adenomas 
and the GC tumors, we believe that our observations warrant the use of the GC tumor bearing rats as 
an animal model to study GH-secreting adenomas, the deleterious effects caused by prolonged exposure 
to elevated circulating GH/IGF-I levels as well as the phenotypic changes that occur after normalization 
of the circulating GH/IGF-I levels by surgical or phamarcological treatment.
Material and Methods
Animal care, graft induction and surgery. All procedures involving experimental animals were 
performed in accordance with local animal welfare laws, guidelines and policies. All experimental pro-
tocols were approved by the IBiS-Virgen del Rocio Ethics Committee. Female Wistar Furth rats were 
purchased from a commercial supplier (Charles River Laboratories, L’Arbresle, France). GC cells were 
obtained from Jacques Epelbaum (INSERM, Centre de Psychiatrie et Neurosciences, Université Paris 
Descartes) and culture conditions have been described elsewhere8. GC tumors were generated were by 
subcutaneous injection of 1 × 107 GC cells (in 0.3 ml of PBS) in the flank of 9-weeks-old rats. Control 
(vehicle-treated) rats were injected with PBS. For surgical removal of the tumor, rats were anesthetized 
with ketamine hydrochloride (40 mg/kg; ip) plus xylazine (8 mg/kg; im). Sham surgery involved an inci-
sion on the contralateral side of the tumor. Follow-up study endpoint was defined as the time that any 
group (tumorectomy, naive tumor, or saline) had reached 50% of survival. Pituitaries and tumor samples 
were obtained from these animals for histology, immunohistochemistry and quantitative real time PCR 
analysis.
[18F] FDG and [11C]MET PET/CT. Commercial IBA-Molecular Flucis® [18F]fluorodeoxyglucose [18F]
FDG was used for glucose metabolism evaluation. The radioligand [11C]L-Methionine [11C]Met was 
prepared by reaction of L-homocysteine thiolactone hydrocloride with [11C] Methyl iodide as previously 
reported59 but [11C] Methyl iodide was obtained in gas form. The decay-corrected radiochemical yield 
was about 32% (End of Bombardment), the radioactive concentration was 3.97 ± 0.19 GBq/mL at the 
moment of injection, and radiochemical purity was greater than 99%. pH was at pharmacopoeia range 
(4.5–8) in all batches. A dose of 50–100 MBq for each rat was used for all radiotracers. PET scans were 
performed with a high-resolution Philips Mosaic HP preclinical PET system (Philips Medical Systems, 
Eindhoven, The Netherlands) with a field of view of 128 × 120 mm. Before tracer injection, rats were 
pre-warmed to a body temperature of 37 °C and anaesthetised with inhalation of isoflurane-oxygen gas 
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mixture (2% isoflurane, 0.5 l/min oxygen). Rats were kept under anaesthesia for the entire experimen-
tal procedure using a Minerve Animal Anaesthesia System (Equipement Vétérinaire Minerve, Esternay, 
France). Body temperature was maintained at 37 °C throughout the uptake period. Radiotracers were 
administered intravenously through a custom-made catheter placed in the lateral tail vein. Static PET 
imaging was performed 45 min after [18F]FDG injections. Three full body scans (3 × 15 min) starting 
from tumor location in the hind leg was performed. For dynamic [11C]Met-PET imaging, rats were 
injected at the start of the acquisition. CT scans were performed using a Bioscan NanoCT scanner 
(Bioscan, Paris, France) after each PET scan using a transferable animal bed so that animals were kept 
in the same position to allow accurate subsequent fusion of PET and CT image datasets. Images were 
acquired at 45 kVp, 123 μ A current with 500 ms exposition, 240 projections per rotation that permitted 
uniform 0.2 mm image resolution. PET and CT images were fused within PMOD program (version 
3.309). CT images were calculated in Houndsfield units, and PET images in SUV units. An ellipsoidal 
VOI was drawn around the tumor, moved and rotated to encompass full tumor and to avoid nearby 
regions with high activity. Automatic VOI was calculated at the level of 50% of maximum standardized 
uptake value (SUV) minus minimum SUV in the elliptical initial region. The calculated VOI was used as 
an estimation of tumor volume, x-y-z dimensions and maximum FDG. Quantitative PET imaging results 
are also reported in terms of with SUV median (median of pixel SUV values within a defined region 
of interest). For kinetic analysis with [11C]Met, distinct regions of interest were drawn from the center 
of the tumor, the periphery and the muscle of the left hind leg. Time–activity curves were calculated 
for each of these regions and expressed as a mean SUV and KBq/cc. Kinetic analysis was performed by 
fitting a standard 2-parameter, one-tissue compartment model to the dynamic PET data as previously 
described60. The parameters calculated included transport from arterial plasma to tissue (k1) and trans-
port from tissue to arterial plasma (k2). VT was calculated as k1/k2. The whole blood image-derived 
input function used for kinetic calculation was obtained from the tail vein of the rat.
Hormone measurements. For in vivo hormone measurements, blood from the subclavian vein was 
collected and centrifuged to obtain serum. GH, IGF-I and prolactin levels were measured by ELISA com-
mercial kits (EZRMGH-45K, Merck Millipore, Madrid, Spain; AC-18F1, Immunodiagnostic Systems, 
Ortho Clinical Diagnostics, Rochester, USA; A05101, Bertin Pharma, Montigny le Bretonneux, France).
Tissue preparation, Histology, Immunohistochemistry and Microscope Analysis. Tumor 
specimens were fixed in 4% (wt/vol) paraformaldehyde (PFA) in phosphate-buffered saline (PBS) at 
4 °C overnight. Pituitaries were fixed in 4% PFA in PBS at room temperature for 1 hour. Tissues were 
washed three times in PBS, rinsed in 70% ethanol and processed for paraffin embedding in a tissue 
processor (ASP200S, Leica, Barcelona, Spain). Immunohistochemical analysis was performed as previ-
ously described61. Briefly, following dewaxing, rehydrating and pressure-cooker antigen retrieval, paraffin 
sections were permeabilized in 0.2% Triton X-100 in PBS (PBT) and blocked in 3% donkey serum in 
PBT (60 minutes at room temperature). Tumor and pituitary sections were then incubated with pri-
mary antibodies at 4 °C overnight, washed three times in PBS and incubated with secondary antibodies 
coupled with the appropriate conjugated secondary IgG antibody (45 minutes at room temperature). 
Primary antibodies are listed in supplementary material Table S2. Staining for diaminobenzidine (DAB) 
was performed with the ABC Elite immunoperoxidase system (Vector Laboratories). When further 
amplification was required, the EnVision enzyme-conjugated polymer (DAKO, Barcelona, Spain) was 
used. Sections were counterstained with Mayer’s hematoxylin (Bio Optica, Milan, Italy), dehydrated and 
mounted with DPX mountant for histology (Sigma-Aldrich, Madrid, Spain). Hematoxylin/eosin staining 
was performed as previously described62. Bright field images were acquired using a BX61 microscope 
(Olympus, Japan). All photomicrographs shown are representative of at least three independent samples. 
Confocal images were acquired with a LSM-7 DUO microscope (Zeiss, Germany). For 3D reconstruc-
tion, Z-stack confocal images were reconstructed using Imaris (Bitplane).
SA-β-galactosidase Activity. SA-β -Gal staining was performed in whole-mount tumors or in 
tumor cryosections preserved in OCT. For whole-mount staining, freshly dissected tumors were cut 
into 1–3 mm pieces and fixed with a solution containing 2% PFA and 0.2% glutaraldehyde in PBS (pH 
6.0) for 2 h on ice. Samples were washed three times with PBS and tissue was incubated overnight in 
SAβ gal staining solution containing X-gal in N-N-dimethylformamide (pH 6.0) at 37 °C. The following 
day, the samples were washed with PBS then fixed in 4% PFA overnight at 4 °C. Tumor samples were 
subsenquently dehydrated with two consecutive steps in 50% and 70% ethanol and embedded in paraffin 
for serial sectioning. 5 μ m sections were cut, counterstained with nuclear fast red (Sigma) or were pro-
cessed for immunohistochemistry as described above with the exception that slides were counterstained 
for 30 s with nuclear fast red. Detection of SA-β -gal activity in cryosections was performed as previously 
described63.
Western Blot analysis. Pituitary and GC tumor samples were lysed and homogenized in lysis solu-
tion (20mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% Igepal, 0,1% SDS, 0,5% Deoxycholate, 
Complete Ultra protease inhibitors (Roche) and PhosphoSTOP phosphatase inhibitors (Roche). After 
SDS-PAGE separation, samples were transferred to PVDF membranes (BioRad). Immunoblots were 
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developed using HRP-conjugated secondary antibodies (Jackson) and enhanced chemiluminescent 
(Thermo #34096). ImageQuant LAS 4000 Mini and Image Quant TL (GE Healthcare) were used for 
imaging and quantification. Antibodies used for immunoblotting were p16 (Santa Cruz Biotechnology 
#sc-1207) and p18 (Santa Cruz Biotechnology #sc-865). Anti-ß-actin (clone AC74, Sigma-Aldrich 
#A2228) was used as loading control.
RNA isolation and Quantitative Real Time PCR. Nucleic acid isolation was performed using 
Absolutely RNA RT-PCR Miniprep Kit (Agilent, La Jolla, CA, USA) with deoxyribonuclease treat-
ment, following manufacturer’s instruction. Total RNA purity and concentration was assessed using 
Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, NC, USA), and subsequently 
reverse-transcribed using random hexamer primers and the cDNA First Strand Synthesis kit (MRI 
Fermentas, Hanover, MD, USA). Quantitative PCR was performed using Brilliant III SYBR Green Master 
Mix in the Stratagene Mx3000p system (Agilent, La Jolla, CA, USA). Details regarding the development, 
validation and application of the qPCR methods in pituitary tissue have been previously described64,65. 
Briefly, in order to perform an absolute quantification of the starting copy number of cDNA for each 
sample examined using SYBR Green methods, reverse-transcribed samples derived from GC tumors 
and normal rat pituitary) were PCR amplified, and the signal was compared with that of an specific 
standard curve run in parallel on the same plate. Standard curves consisted of 1, 101, 102, 103, 104, 105, 
and 106 copies of synthetic cDNA template for each of the transcript examined. Standard curves were 
generated by the Stratagene Mx3000p Software, and the slope of a standard curve for each template 
examined was −3.31 and −3.35 (r2 of the standard curve between 0.997 and 0.999), indicating that the 
efficiency of amplification was close to 100%, meaning that all templates in each cycle were copied. 
qPCR thermal profile consisted of a first step at 95 °C/10 minutes, followed by 40 cycles of denaturation 
(95 °C/30 seconds), annealing (61 °C/60 seconds), and extension (72 °C/30 seconds); and finally, to verify 
that only one product was amplified, a dissociation cycle. To control for variations in the quantity of 
RNA used in the retro-transcription reaction and the efficiency of the RT-reaction, the expression level 
(expressed as copy-number) of each transcript of interest was adjusted by the expression of beta-actin 
[used as a housekeeping gene; mRNA levels of beta-actin did not significantly vary between experimental 
groups (data not shown)]. Specific primers sequence, GenBank accession numbers and product sizes for 
rat beta-actin and somatostatin receptors used in this study were as follows: beta-actin (Actb; forward 
5′ -CCTAAGGCCAACCGTGAAA-3′ and reverse 5′ -CCAGAGGCATACAGGGACAA-3′ , NM_031144.3, 
104 bp), somatostatin receptor 1 (Sstr1; forward 5′ -TGCCCTTTCTGGTCACTTCC-3′ and reverse 
5′ -AGCGGTCCACACTAAGCACA-3′ , NM_012719.2, 135 bp), somatostatin receptor 2 (Sstr2; forward 
5′ -CCCATCCTGTACGCCTTCTT-3′ and reverse 5′ -GTCTCATTCAGCCGGGATTT-3′ , NM_019348.1, 
134 bp), somatostatin receptor 3 (Sstr3; forward 5′ - TTGGCCTCTACTTCCTGGTG-3′ and reverse 
5′ -ATCCTCCTCCTCCTCCGTCT-3′ , NM_133522.1, 185 bp) and somatostatin receptor 5 (Sstr5; for-
ward 5′ -TCATTGTGGTCAAGGTGAAGG-3′ and reverse 5′ -AAGAAATAGAGGCCGGCAGA-3′ , 
NM_012882.2, 199 bp). Based on the stringent criteria to maximize specificity and efficiency, the use of 
qPCR can be used to accurately quantify copy number expression of mRNA transcripts, as previously 
reported40,44,64,65.
Primary cell cultures and in vitro analysis. Primary tumor samples were dispersed into single cells 
by enzymatic/mechanical disruption, and cultured onto tissue culture plates in serum containing medium, 
as previously described66. Briefly, tumor samples were transferred to sterile culture medium (S-MEM, 
Gibco, Madrid, Spain) supplemented with 0.1% BSA, 0.01% L-glutamine, 1% antibiotic-antimycotic 
solution, and 2.5% HEPES. Tumors were minced into 1–2 mm3 pieces using sterile blades, washed and 
incubated in 30 mL S-MEM medium supplemented 0.3% trypsin (Beckson, Dickinson and Company, 
Sparks, MD, USA) for 2 h of gentle shaking at 37 °C in a spinner flask (Bellco Glass, Vineland, NJ, 
USA). Cells suspension was washed twice in 4.5 g/L glucose containing DMEM medium (Gibco, Madrid, 
Spain) complemented with 0.1% BSA, 0.01% L-glutamine, 1% antibiotic-antimycotic solution, and 2.5% 
HEPES. Cell viability (90–100% in all cases) was assessed by the Trypan blue exclusion test in a Neubauer 
chamber.
For in vitro cell proliferation experiments (10,000 cells/well were plated in a 96-well plates), SOM-
230 (generously provided by Herbert A. Schmid; Novartis Pharma AG, Basel, Switzerland), octreotide 
(GP-Pharm, Barcelona, Spain) and sstr2 agonist (BIM-23120; generously provided by Michael D. Culler; 
IPSEN Bioscience, Cambridge, MA, USA) were administered at 100 nM, as previously reported67,68. 
Cell proliferation in response to the given treatments was evaluated using the MTT [3-(4,5-dimet
hylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. After 36 hours of culture, the medium was 
removed and fresh medium containing 1% FBS was added. After 24 h of incubation, treatments were 
added to the cells in 1% FBS containing medium. Proliferation rate was measured after 24, 48 and 
72 hours of incubation. Before measuring, cells were pre-incubated for 2 hours with MTT-containing 
DPSS solution, medium was removed and DMSO solution with SDS and acetic acid was added to the 
cells and incubated in a shaker at 150 rpm for 15 minutes. Measurements were made at 590 nm using a 
Flex Station III (Molecular Devices, Madrid, Spain) coupled to a computer, and the software SoftMax 
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Pro v5.4.1 (Molecular Devices, Madrid, Spain). DMEM containing 1% FBS was used as vehicle-control 
and positive control of inhibition of cell proliferation, respectively.
Similarly, for in vitro secretion experiments, 100,000 cells/well were plated in 24-well plates in 
FBS-containing medium. After 36 hours of culture, medium was replaced for FBS-free medium for 1 hour. 
Then, SOM-230, octreotide and sst2 agonist were administered at 100 nM for 4 h, using FBS-containing 
medium as a control, and media were collected and stored at − 20 °C for further analysis by specific GH 
ELISA.
Statistical analysis. For statistical comparisons two-tailed Student’s test or one-way and two-way 
ANOVA for repeated measures followed by post-hoc Tukey HSD and Bonferroni corrected t-tests. 
Data are presented as mean ± SEM. The Kaplan-Meier survival curves were used for survival analysis. 
Comparisons of survival curves were performed with the logrank test. A P-value less than 0.05 was 
considered significant.
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